Gyms overflowing, menus full of small plates and a surge in 'Ozempic face' supplements are just a few ways in which weight-loss jabs are altering society ...

Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and ...

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Novo Nordisk (NVO) presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic injection 1 mg in adults ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

The deal comes as Novo Nordisk moves to become the leader in ... The Danish maker of Ozempic has dominated the space with its Wegovy, but is facing competition from Eli Lilly's Zepbound (tirzepatide).

Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

In the fourth quarter of 2024, Ozempic sales increased 12% to 33.85 ... This is due to a decline in Novo Nordisk’s market value. Novo Nordisk’s stock price has fallen almost 21% YTD.